Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Tirzepatide reduces HF events in patients with HFpEF and obesity
Tirzepatide reduces HF events in patients with HFpEF and obesity
AHA 2024
Tirzepatide reduces HF events in patients with HFpEF and obesity
- Milton Packer, MD
Acoramidis reduces all-cause mortality in ATTR-CM
Acoramidis reduces all-cause mortality in ATTR-CM
AHA 2024
Acoramidis reduces all-cause mortality in ATTR-CM
- Daniel Judge, MD
NEW EPISODE
Mastering MRA Monitoring: The Key to Success
Mastering MRA Monitoring: The Key to Success
MinuteCE®
Mastering MRA Monitoring: The Key to Success
1.25 program credits
- Akshay S. Desai, MD
- John McMurray, MD
1.25 program credits
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
MinuteCE®
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
0.75 program credits
- James Burton, DM, FRCP
- Aaron Wong, MD
0.75 program credits